IP Library › Patent Application 18339106
Patent Application
App. No. 18/339,106

USE OF CIRCULATING CELL-FREE RNA FOR DIAGNOSIS AND/OR MONITORING CANCER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/339,106
Abstract

The invention provides compositions, methods, and systems for using cell-free RNA for improved detection of rare cells and/or species that are useful for diagnosing and/or monitoring cancer. The invention also provides for compositions, methods, and systems for early detection of cells that are resistant and/or developing resistance to cancer therapies.

Claims (18)

1 . A method for detecting mRNA of a biomarker in a biological sample from an individual, the method comprising:

a. isolating cfRNA from the biological sample on a solid support, wherein the blood sample has been interacted with RNA stabilizer;

b. digesting DNA from the biological sample while the cfRNA is on the solid support;

c. eluting cfRNA at least once from the solid support;

d. reverse transcribing the cfRNA to cDNA;

e. reacting the cDNA with at least one primer that is specific for

i. a gene mutation specific to the biomarker, or

ii. a fusion transcript of the biomarker, or

iii. gene expression of the biomarker; and

wherein the biomarker is selected from the group consisting of ERCC1, EGFR, TS, AREG, EREG, VEGFR2, EML4ALK, ROS1, RET, c-Met, FGFR1, KRAS, BRAF, NRAS, Her-2, PIK3CA, KIT, GNAQ, and GNA11.

2 . The method of claim 1 wherein the eluate of step (c) is passed over the same column for a dual elution prior to the reverse transcribing the cfRNA to cDNA.

3 . The method of claim 1 wherein the individual has or is suspected of having cancer.

4 . The method of claim 1 , wherein the biological sample is a blood sample or a plasma sample.

5 . The method of claim 4 , wherein the plasma sample is processed within 7 days of interacting with the RNA stabilizer.

6 . The method of claim 1 wherein random hexamers are used in step (d) to reverse transcribe the RNA to cDNA.

7 . The method of claim 1 , further comprising sequencing the cDNA.

8 . The method of claim 7 , wherein the sequencing comprises polymerase chain reaction (PCR)-based sequencing.

9 . The method of claim 8 , wherein the PCR-based sequencing is next generation sequencing.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2025
From: DANENBERG, KATHLEEN
To: LIQUID GENOMICS, INC.
Reel/Frame 073203/0478 →